1. Home
  2. EHTH vs SCYX Comparison

EHTH vs SCYX Comparison

Compare EHTH & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EHTH

eHealth Inc.

HOLD

Current Price

$1.42

Market Cap

52.4M

Sector

Finance

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.00

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHTH
SCYX
Founded
1997
1999
Country
United States
United States
Employees
N/A
29
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.4M
42.4M
IPO Year
2006
2014

Fundamental Metrics

Financial Performance
Metric
EHTH
SCYX
Price
$1.42
$4.00
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$3.33
$3.00
AVG Volume (30 Days)
529.1K
94.2K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
71.43
61.36
EPS
N/A
N/A
Revenue
$251,395,000.00
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.60
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
45.86
N/A
52 Week Low
$1.20
$0.57
52 Week High
$5.89
$5.62

Technical Indicators

Market Signals
Indicator
EHTH
SCYX
Relative Strength Index (RSI) 38.78 47.27
Support Level $1.43 $3.68
Resistance Level $1.58 $5.62
Average True Range (ATR) 0.13 0.39
MACD -0.02 -0.12
Stochastic Oscillator 2.63 4.47

Price Performance

Historical Comparison
EHTH
SCYX

About EHTH eHealth Inc.

eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is derived from the United States. It also has a presence in China.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: